Copyright
©The Author(s) 2025.
World J Cardiol. Apr 26, 2025; 17(4): 104465
Published online Apr 26, 2025. doi: 10.4330/wjc.v17.i4.104465
Published online Apr 26, 2025. doi: 10.4330/wjc.v17.i4.104465
Table 3 Summary of the main findings of included studies
Ref. | Antiarrhythmic medication before ivabradine | Treatment with ivabradine (Dose) | Antiarrhythmic medication with ivabradine | Outcomes of treatment with ivabradine | Adverse effects following ivabradine administration | Recurrence |
Upreti et al[16] | Adenosine, amiodarone | 0.1 mg/kg/dose twice a day | Amiodorane, monotherapy at discharge | SR, HR control | None | _ |
Devaprasath et al[9] | Adenosine | 0.1 mg/kg/dose twice a day | None | SR, HR control, JR intermittent | None | Not noticed within 2 weeks of follow up |
Asfour et al[10] | Propranolol, amiodarone | 0.05 mg/kg/dose twice a day, decreased to 0.04 mg/kg/dose twice a day, at discharge 008 mg/kg/d | Propranolol, amiodorane; monotherapy at 2nd week | SR, HR control | Bradycardia prior to monotherapy | Not noticed within 6 months of follow up |
Di Marco et al[8] | Amiodarone, flecainide, propranolol | 0.25 mg/kg/day (with propranolol, amydarone), 0.3 mg/kg/day (with flecainide) | Propranolol, amiodorane, flecainide | HR control, SR (with flecainide) | None | _ |
Ríos et al[17] | Amiodarone, propranolol, n = 2; flecainide, n = 1 | 0.05 mg/kg/dose, at discharge 0.1 mg/kg/day | Amiodorane, propranolol (discontinued later) | SR/JR, HR control | None | _ |
Michel et al[15] | Adenosine, Flecainide, Amiodarone, Esmolol | 0.025 mg/kg/dose twice a day, increased to 0.05 mg/kg/dose | Esmolol (discontinued later), metprolol | HR control, SR/EAR | None | _ |
Kothari et al[13] | Amiodarone, flecainide, n = 2; propranolol, enalapril, metoprolol, n = 1 | 0.05 mg/kg/dose twice a day | Amiodarone, flecainide, n = 2; propranolol, enalapril, metaprolol, n = 1 | SR, HR control | None | _ |
Ergul et al[18] | Flecainide, amiodarone, digoxin, n = 1; Flecainide, amiodarone, propranolol, n = 2 | 0.1 mg/kg/day | Amiodarone, n = 1; Amiodarone, propranolol, flecainide, n = 2 | HR control, n = 3; SR control, n = 2; JR/SR control, n = 1 | None | _ |
Dieks et al[7] | Amiodarone, n = 5; flecainide, n = 1; digoxin, n = 2 | 0.05-0.1 mg/kg/dose increased to 0.28 mg/kg/dose | Amidarone, n = 5; propranolol, amidarone, n = 2; digoxin, amiodarone, n = 1 | HR control, n = 5; SR, n = 2; JR/JET, n = 1; JR/SR, n = 1 | None | _ |
Alghamdi et al[21] | Flecainide, sotalol, procainamide, amiodarone | 2.5 mg once daily | None | SR, HR control | None | _ |
- Citation: Bokhari SFH, Mushtaq MM, Mushtaq M, Ali H, Bakht D, Faizullah M, Asghar A, Buhadur Ali MK, Sarwar MA, Liaqat M, Iqbal A, Dost W. Ivabradine in the treatment of congenital junctional ectopic tachycardia: A systematic review. World J Cardiol 2025; 17(4): 104465
- URL: https://www.wjgnet.com/1949-8462/full/v17/i4/104465.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i4.104465